Tests lung fluid monitoring to help manage heart failure in primary care
Tests a non-invasive lung fluid check guiding heart failure care in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Effect of Non-Invasive Lung Fluid Monitoring for Heart Failure Management in Primary Care
Key facts
- Where
- Flen, SwedenSee the site
Where in Sweden
- Primary care center Centrum FlenFlen, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Linkoeping University
- Trial code
- NCT06734065
- Record updated
- 27 April 2025
- Original description
Remote dielectric sensing (ReDS) technology offers a non-invasive method for assessing lung congestion. This randomized controlled trial aims to evaluate the effectiveness and processes of the ReDS-guided heart failure management program in primary care settings for patients with heart failure.Read full original descriptionShow less
Effect of Non-Invasive Lung Fluid Monitoring Using ReDS Technology for Heart Failure Management in Primary Care Settings: A Randomized Controlled Trial
Remote dielectric sensing (ReDS) technology offers a non-invasive method for assessing lung congestion. This randomized controlled trial aims to evaluate the effectiveness and processes of the ReDS-guided heart failure management program in primary care settings for patients with heart failure.
Inclusion: Age ≥ 18 years, there is no upper age limit; Diagnosed with heart failure regardless of left ventricular ejection fraction; Having New York Heart Association (NYHA) Class III/IV irrespective of prior hospitalisation for heart failure, or NYHA II with a history of at least one hospitalisation for heart failure within the previous 12 months; Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) within 12 months: (a) ≥450 pg/ml for patients under 50 years; (b) ≥900 pg/ml for patients aged 50-75 years; (c) ≥1800 pg/ml for patients over 75 years.
Exclusion: Implantation of a left ventricular assist device or cardiac transplantation; NYHA I; Life expectancy <6 months; Physical characteristics that prevented use of the ReDS (body mass index < 22 or >39, and height less than 155 cm or higher than 195 cm).